In HCC, LRP1B mutation significantly associated with a higher HHLA2 (human endogenous retrovirus-H long terminal repeat-associating protein 2), as well as with TMB, giving new insights into potential targets for immune checkpoint inhibition [61]. The gene discussed is LRP1B; the disease is hepatocellular carcinoma.